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Flow diversion prostheses represent a new endovascular approach aimed at treating patients with large wide-neck aneurysms.
Our objective is to present this new technology, to review the clinical studies on eﬃcacy, and to emphasize its current limits.
Flow diversion prostheses consist of a cylinder made of a large number of braided microﬁlaments providing a large metallic
surface when deployed and inducing a blood ﬂow diversion outside the aneurysm. Two diﬀerent brands are currently available.
Clinical data supporting their eﬃcacy are currently limited to six non comparative cohort studies that included between 18 and
107 patients. Procedural implantation was shown to be feasible in more than 90% and safe with a thirty-day mortality between 2.8
and 5.5%. Complete occlusion rates at twelve months varied between 85.7 and 100%. Even though promising, the current status of
ﬂow diversion prostheses needs further evaluation with randomized, prospective, clinical trials with comparison to conventional
strategies including endovascular coiling or surgical clipping.
1.Introduction
According to a systematic review based on 23 studies, the
incidence of unruptured intracranial aneurysm (UIA) is
about 2% in the general population, greatly represented by
saccular shapes [1]. Whereas individually unpredictable, the
risk of rupture is estimated to be 1.2% per year, but it
increases up to 6% depending among others on aneurysm
diameter or localization [2]. Consequences of rupture are
dramaticbothintermsofmortality(30–67%)andmorbidity
(15–30%) [3, 4]. That is why, despite a lack of clinical
evidence based on randomized studies [5], it is generally
accepted that patients with UIA and major risk factors
of rupture should receive a preventive treatment whenever
possible [6].
Diﬀerent approaches are then possible [7]. The conven-
tionalsurgicalapproachconsistsofperformingacraniotomy
followed by a clip ligation, also called microsurgical clipping.
Since the nineties, endovascular occlusion using detachable
coils, also called coiling, has emerged as an alternative to sur-
gical clipping [8]. Endovascular coiling has been increasingly
used because it is thought to be eﬃcient to prevent bleeding
with a low rate of complication and minimal invasiveness
in comparison to surgical clipping although these alleged
advantages versus surgery are not supported by prospective,
randomized, clinical trials but only studies with low level of
evidence[8].Furthermore,itslong-termeﬃcacyparticularly
in large wide-neck aneurysm is still debated. Indeed, despite
the availability of a wide range of embolization devices
and the improvement of procedures using balloon or stent
assistance [9, 10], endovascular coiling is hampered mainly
because of the high incidence of reopening over time. In a
recent meta-analysis, reopening rate was reported at 20%,
twelve months after endovascular treatment of large wide-
neck UIA, and the rate of retreatment was 10% [11, 12].
Furthermore, the large number of coils implanted may2 International Journal of Vascular Medicine
Figure 1: SILK stent (BALT Extrusion Inc.).
induce a mass eﬀect responsible for the worsening of the
patient’s condition. In practice, the management of unrup-
tured, large, wide-neck aneurysms remains challenging.
In this context, a new endovascular technique using
ﬂow diverter stents has emerged in the last four years. Our
objectivesaretopresentthepotentialinterestandthecurrent
limits of this technique in the management of UIA.
2. Deﬁnition and Presentationof
theTechnology
Flowdiversion prosthesesrepresentanewapproachaimedat
treating patients with large wide-neck aneurysms. They con-
sist of a cylinder made of a large number of braided microﬁl-
aments providing a total metallic surface of up to 30%, when
deployed, as opposed to 10% for conventional intracranial
stent. Once implanted in the parent artery across the neck,
they induce a blood ﬂow diversion outside the aneurismal
sac. Since blood ﬂow inside the aneurysm decreases, a pro-
gressive thrombosis is observed over time [13, 14].
Two diﬀerent brands have been developed over the
last four years. The ﬁrst one is called “SILK” prosthesis
(BALT Extrusion Inc.). It is made of 48 braided nitinol and
platinium strands that form a high-coverage cylinder once
deployed. It exists with diﬀerent diameters (2 to 5mm) and
lengths (15 to 40mm) (Figure 1). The SILK stent system
includes a self-expanding stent, a delivery system, and a rein-
forced catheter for its placement. It is repositionable when
deployed up to 90%. The SILK stent has received an approval
in the European Community.
The second one is called pipeline embolization device or
PED(EV3Inc.).Itisdeliveredthroughastandard0.027-inch
internal diameter microcatheter and enables a endovascular
“stent-like” construct. The PED has 48 microﬁlaments made
of platinum and nickel-cobalt chromium alloy.(Figure 2). Its
diameters are rather similar to the SILK stent (2.5mm to
5mm), and the lengths go from 10 to 35mm.
The PED has received a European Community and a
Food and Drug Administration (FDA) approvals.
The procedures are performed under general anaesthesia
and use a transfemoral artery approach. Unexpanded ﬂow
diversion stents inserted in the loading device are positioned
up the aneurysm and delivered under ﬂuoroscopic guidance.
Similarly to conventional stenting, patients receive dual
antiplatelettherapy(clopidogrelandaspirin)topreventstent
thrombosis prior to the procedure and forat least six months
after the procedure.
Figure 2: Pipeline embolization device (EV3 Inc.).
This concept of ﬂow diversion stents may be considered
as a breakthrough technology since the prostheses enable an
intravascular reconstruction in comparison to the intrasac-
cular approach.
3. ClinicalEfﬁcacyand Tolerance Data
3.1. Methods. PubMed electronic database was queried in
order to search for articles on clinical eﬃcacy and tolerance
data. The following key words were used in combination:
“ﬂow diverters stents,” “PED,” “pipeline embolization device,”
“SILK stent,” and “unruptured aneurysm.” The FDA website
was also consulted.
3.2. Results. Fiorella et al. published the ﬁrst two experiences
reporting a successful use of pipeline embolization device
in a total of three patients with either giant sacciform or
fusiform symptomatic intracranial aneurysm [13, 14]. Its
European Community approval was obtained on the basis of
the PITA trial (pipeline embolization device in the intracranial
treatment of aneurysms). This cohort study was conducted
in four centres and included a total of 31 patients with
large wide-neck aneurysm (mean size: 11.5mm, mean neck
size: 5.8mm). Procedural success estimated by successful
implantation without immediate complication was 97.9%.
The six-month complete occlusion rate was 93.3% [15].
The main complication was the occurrence of two ipsilateral
strokes within the 30 days after procedure.
The FDA approval of PED was recently obtained based
on the results of the PUFS (pipeline for uncoilable or failed
aneurysms)study.Thisprospectivesingle-arminterventional
study included a cohort of 107 patients with large and giant
aneurysms (mean size: 18.2mm, mean neck size: 8.8mm).
Procedural success implantation was 99%. The primary
eﬀectiveness endpoint consisting of complete occlusion rate
at 180 days without major stenosis was 73.6%.
The proportion of subjects with major ipsilateral stroke
or neurologic death at 180 days after treatment was 5.6%.International Journal of Vascular Medicine 3
Table 1: Summary of clinical trials conducted on ﬂow diversion stents.
Device SILK stent (BALT) Pipeline embolization device (EV3)
Number of centres 3 18 4 10 1 1
Number of patients 29 70 31 107 53 18
Number of aneurysms 34 70 31 107 63 19
Number of small/large/giant aneurysms 18/12/4 18/37/15 20/9/2 0/85/22 33/22/8 5/10/4
Procedural success implantation 90% 96% 97. 9% 99% 97%
Adjunctive coil placement 0% 14% 51.6% 1% 6% 47%
Number of stent implanted per patient 1.42 / 1.35 3.1 1.37 2.16
30 days mortality rate 4% 2.8% 0 2.8% 0 5.5%
3- or 6-month complete occlusion rate 69% 50% 93% 81.8% 93% 94%
12-month complete occlusion rate / 100% NA 85.7% 95% /
Reference [20][ 19][ 15][ 16][ 17][ 18]
The PUFS study was then able to show safety and eﬃcacy of
PED in large or giant wide-neck aneurysms [16].
The results of two single-centre experiences are also
available. A study from Lylyk et al. reported the use of PED
in 53 patients treated in the Department of Neuroradiology
of Buenos Aires [17]. Forty-four patients were treated by
one PED, while 17 and two received two and three PEDs,
respectively. In 6% of the cases, endovascular coils were
associated. The angiographic complete occlusion rates at
six and 12 months were 93% and 95%, respectively. No
periprocedural or serious adverse event was observed at
30 days. The rate of minor complications was 11% and
mainly consisted in haematoma at femoral puncture site.
In the Budapest experience, 18 patients with an important
proportion of giant aneurysms were treated with PED. An
impressivecompleteocclusionrateof94%wasobservedwith
a minor incidence of complications. Forty-seven percent of
patients received adjunctive coil placement [18].
In those cohort studies, more than one stent placement
was observed on average, depending on the size of the an-
eurysm or the level of perioperative blood ﬂow diversion
observed on angiography.
The clinical experiences related to the use of SILK stent
a r em o r el i m i t e d .
An 18-centre worldwide experience was published on 70
patients presenting an aneurysm and considered as ineligible
for conventional endovascular or neurosurgical treatment
[19]. The procedures using SILK stent were shown to be fea-
sible with an implantation success of 96% and an acceptable
mortality rate of 2.8% with regards to the high proportion
of large or giant aneurysm. At 12 months, an impress-
ive complete occlusion rate of 100% was observed, but long-
term followup yet concerns a limited number of patients.
Another experience of Lubicz and colleagues is published
on 29 patients considered not eligible to other endovascular
approaches (47% of fusiform or circumferential shape
aneurysm) [20]. The procedural implantation success was
90% with a mortality rate of 2.8%. Angiographic followup
available at three or six months reports a complete occlusion
rate of 69%.
The six cohort study experiences are summarized in
Table 1. Comparisons between ﬂow diversion prostheses are
not possible not only because criteria for patient selection
were not similar, but also because endovascular procedures
were diﬀerent in terms of adjunct coil placement.
4. Discussion
4.1. Current Limits. The theoretical interest of ﬂow diversion
stentsistoenableendovascularreconstructionwhenconven-
tional approaches, mainly represented by endovascular coil-
ing or surgical clipping, are not technically feasible or not
appropriate because of a major risk of morbidity or recur-
rence over time. It is expected to relieve neurological symp-
toms due to mass eﬀect and to decrease aneurismal recur-
rences over time. Even though promising and representing
a breakthrough technology, the current knowledge on ﬂow
diversion prostheses is still limited, and their respective
positioning in routine practice must be further evaluat-
ed.
First, questions may be raised on the technical procedure
by itself. More precisely, there is currently no guideline
regarding the number of stents needed to be implanted and
the interest of adjunctive coil placement. The number of
stents to implant will ﬁrst depend on the aneurismal neck.
In very large or giant aneurysm, the length of one ﬂow
diverter stent may be not suﬃcient to cover all the aneu-
rysm, and therefore, several stents may be required. For
example, Fiorella and colleagues reported the use of seven
serialtelescopedPEDstobridgea29mmdiameteraneurysm
[14]. The level of immediate blood ﬂow diversion expected
after stent placement is not clear, and therefore, the need
to further add a second stent inside the ﬁrst one (“in-
stent” stenting) to increase blood ﬂow diversion can be dis-
cussed. Table 1 shows that the number of stents required per
aneurysm greatly varies between studies, and it seems to be
dependent on each neuroradiologist’s experience.
T h es e c o n dd e b a t ei so nw h e t h e ra n ya d j u n c t i v ec o i l
placement should be necessary.
Recently, Turoswki and colleagues reported an early fatal
haemorrhageduetheaneurysmruptureaftervascularrecon-
struction using the SILK stent without any coils associated
[21]. Obviously, it is impossible to know if adjunctive coil4 International Journal of Vascular Medicine
placement could have prevented this rupture. If so, would
one, two, or more coils be necessary? Until more clinical data
is available, this question is still debated.
The current positioning of ﬂow diversion prostheses in
the strategy is also to be evaluated.
Firstly, clinical experiences reporting the use of ﬂow
diverters are limited to noncomparative cohort studies in-
cluding between 18 and 107 patients. Thus, there is cur-
rently no head-to-head comparison of ﬂow diversion pros-
theses versus other conventional approach, including endo-
vascular coiling or surgical clipping in large wide-neck aneu-
rysm in terms of long-term angiographic and clinical out-
come.
Furthermore, ﬂow diversion prostheses are expected to
improve quality of life of patients due to the suppression of
mass eﬀect-associated symptoms, but no comparative data is
currently available versus endovascular coiling.
A long-term view on tolerance is needed to accurately
determine the real incidence of secondary rupture or the risk
of stent thrombosis. Whereas certainly rare, this latter comp-
lication is possible as illustrated by Fiorella et al. concerning
a very late thrombosis in a patient treated with PED [22].
At last, taking into consideration their substantial cost
(approximately C10,000 per stent in Europe, i.e., about US
$14,000) and the number of stents required per patient, the
economic impact of ﬂow diversion stents should be further
evaluated through cost-beneﬁt analysis.
4.2. Perspectives. Several randomized clinical trials are now
ongoing to improve knowledge on this technology.
Taking into consideration that most of patients with
large wide-neck aneurysm are suitable for conventional ap-
proach,therandomizedFIATtrial(ﬂowdiversioninintracra-
nial aneurysm treatment) will compare the clinical outcome
between ﬂow diversion and best standard treatment includ-
ing endovascular coiling or surgical clipping [23]
In patients for whom an endovascular treatment is
decided, three clinical trials are ongoing or planned. A ﬁrst
onecalledCOCOA(completeocclusionofcoilableintracranial
aneurysms) is being conducted in the United States to
compare PED versus endovascular coiling in small wide-
neck aneurysm [24]. In Europe, the MARCO POLO trial
is comparing the SILK prosthesis reconstruction versus
endovascular coiling in large wide-neck aneurysm [25]. The
EV IDENCE trial is about to compare the PED versus
endovascular coiling (with or without balloon or stent
assistance) in large wide-neck aneurysm in a prospective,
multicentric, randomized study. This French trial promoted
by Lyon University Hospital will be aimed at evaluating the
two strategies both in terms of clinical and economical end-
points in order to measure the incremental cost-eﬀectiveness
ratio of PED versus endovascular coiling.
5. Conclusions
Endovascular reconstruction using ﬂow diversion prostheses
is a highly innovative technique for the treatment of patients
with UIA. Whereas promising, many questions still remain
regarding this technique by itself and its current positioning
in the strategy. Flow diversion prostheses are indicated in
rare clinical situations such as giant or fusiform aneurysm
in which no acceptable therapeutic approach exists, and
their interest in the management of large aneurysm should
be evaluated prospectively with comparison to conventional
techniques, including endovascular coiling or surgical clip-
ping.
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